The goal of this study is to evaluate the real-world outcomes of intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment in diabetic macular edema (DME) patients.

The study included patients who were being observed in the retina departments of 8 tertiary hospitals in the Northern Marmara Region of Turkey (Istanbul's Asian Side, Kocaeli, and Sakarya). The records of DME patients treated with an anti-VEGF agent between January 2015 and December 2018 were reviewed.

Inclusion Criteria:

• Diabetic macular edema treated with intravitreal anti-VEGF injection
• Having at least 4 or more annual examination visits

Exclusion Criteria:

• Phacoemulsification surgery in the last 1 month
• PRFK / grid / focal / micropulse in the last 4 months
• Previous intraocular surgery (excluding PPV and phacoemulsification)

The records of DME patients treated with an anti-VEGF agent between January 2015 and December 2018